SignalXSignalX

ARQT Arcutis Biotherapeutics, Inc.

8-K Current Report
Filed: February 25, 2026
Health Care
Pharmaceutical Preparations
Arcutis Biotherapeutics, Inc. Overview

Arcutis Biotherapeutics, Inc. (ARQT) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 2025 earnings press release issued Feb 25, 2026 — full results in Exhibit 99.1
  • • Dermatology-focused biopharma; revenue trajectory and path to profitability key investor focus given commercial-stage products (ZORYVE line)

Get deeper insights on Arcutis Biotherapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.